Navigation Links
Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Date:5/5/2009

e neuraminidase or "NA" proteins, which stimulate the body to produce antibodies that neutralize influenza virus and prevent spread throughout the cells of the respiratory tract -- and the matrix 1 or "M1" virus that stimulates cytotoxic T lymphocytes to kill cells that may already be infected. This three-pronged approach may offer an advantage over existing vaccines which contain mostly HA with variable and typically low quantities of NA and M1. Further, the VLPs are not made from a live virus and have no genetic material in their inner core, which renders them incapable of replicating and mixing with other influenza viruses.

The current study was planned before the recent outbreak of the 2009 H1N1 influenza virus in North America, which has since spread around the globe. In response to the outbreak, Novavax is making a VLP vaccine candidate against the outbreak strain. Using Novavax's recombinant technology, the VLPs will be genetically matched to the H1N1 influenza strain recommended by CDC, with the potential to induce specific and protective immunity. Further, the VLP approach has the potential of a rapid response as vaccine may be made and released for administration within 12 weeks of knowing the genetic sequence of the outbreak strain.

"We are delighted to have initiated the second clinical study of our seasonal influenza vaccine program", said Dr. Rahul Singhvi, President and CEO of Novavax. "The initiation of this study of the 2008-2009 VLP vaccine highlights our ability to create and manufacture VLPs against multiple influenza strains. Including this study, we now have created and evaluated the safety and immunogenicity of VLPs against seven different strains of influenza in clinical trials. This experience has been of great value as we continue our efforts to create a VLP vaccine against the recently emerged 2009 H1N1 influenza virus".

About Novavax

Novavax, Inc. is a clinical stag
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Early Retirement of $17 Million of Convertible Debt
3. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
4. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
5. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
6. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
8. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
9. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
10. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
11. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ), ... for the detection of foodborne pathogens,  today announced that ... America Merrill Lynch 2015 Health Care Conference on May 12 ... at the Wynn, Las Vegas NV. ... be available through the investor relations section of Roka Bioscience,s ...
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... (Nasdaq: QGLY ) today reported net sales from ... June 30, 2008,compared to $2.2 million reported for the ... ended June 30, 2008, net sales were $7.4 million,compared ... June 30, 2007., 2008 net sales were influenced ...
... have devised a way to squeeze light into tighter ... new technology in the fields of optical communications, miniature ... in passing light through gaps 200 nanometers wide, about ... hair. A group of UC Berkeley researchers led by ...
... July 30 /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. (OTC ... the leading plasma-based pharmaceutical companies in the,People,s Republic ... 2008, it has appointed Mr. Sean Shao, Dr. ... independent members of its Board of Directors, and ...
Cached Biology Technology:The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 2The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 4The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 5The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 6New technique to compress light could open doors for optical communications 2New technique to compress light could open doors for optical communications 3China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 2China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 3China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 4
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... F.L. MARCH 27, 2009 The founder of a ... genetic tests in making medical decisions is the 2009 ... for lifetime achievement in the field of genetic sciences. ... the University of Washington School of Medicine in Seattle, ...
... Scripps Research Institute has obtained the first glimpse of a ... cells. The protein, called P-glycoprotein or P-gp for short, is ... chemotherapy drugs. Understanding its structure may help scientists design more ... March 27, 2009, issue of the journal Science . ...
... new drug developed at the University of California, Davis ... II of human clinical trials to evaluate its efficacy. ... (s-EH) inhibitor, is "a first-in-class drug which may treat ... entomologist Bruce Hammock, who with UC Berkeley cell biologist ...
Cached Biology News:Roberta A. Pagon receives lifetime award in genetics from March of Dimes 2Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 2Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 2UC Davis bench-to-bedside research: Promising treatment in clinical trials 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 4UC Davis bench-to-bedside research: Promising treatment in clinical trials 5
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... The Bio-Plex maintenance, calibration, and ... a custom 96-well plate used ... and calibration procedures using the ... MCV plate is for use ...
... is the first biological reagent ... them, and not just by ... only anti-mycoplasma agent that can ... stocks directly. The cytotoxicity of ...
A component of the Acridinium protein labeling kit....
Biology Products: